Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

Recruiting Phase 1 Interventional Study
EBV-associated Hemophagocytic Lymphohistiocytosis EBV Infection
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 – 60
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
9 (estimated)
Sponsor
Chinese PLA General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) or EBV infection

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age 1-60 years, gender unlimited. * Diagnosed with EBV associated-hemophagocytic lymphohistiocytosis (HLH) or EBV infection. * Fully understood and informed the study and signed the ICF. * Karnofsky Score ≥ 70(age ≥16y) or Lansky Score ≥ 50(age\<16y). * TCRT-T cell donor inclu…
Contacts

Daihong Liu, Doctor

+86 18301339032

daihongrm@163.com

CONTACT

Liping Dou, Doctor

+8613681207138

lipingruirui@163.com

CONTACT